Results 171 to 180 of about 45,078 (254)

Quantitative Monitoring Maximizes Cost-Saving Strategies When Antagonizing Neuromuscular Block With Sugammadex. [PDF]

Cureus
Haberkorn S, Twite M, Klockau K, Whitney G, Faulk DJ.   +4 more
europepmc   +1 more source

AGRN‐, LRP4‐, MUSK‐Related CMS: Clinical, Neurophysiological, Morphological, Genetic and Pathological Mechanisms

Muscle &Nerve, EarlyView.
ABSTRACT Congenital myasthenic syndromes (CMS) are inherited disorders caused by mutations in genes encoding proteins essential for neuromuscular junction (NMJ) function. Pathogenic variants have been identified in more than 35 genes, underscoring the complexity of synaptic biology and the wide range of mechanisms that can compromise neuromuscular ...
Rocio‐Nur Villar‐Quiles, Damien Sternberg, Marie‐Christine Nougues, Arnaud Isapof, Bruno Eymard, Stéphanie Bauché   +5 more
wiley   +1 more source

Sugammadex or neostigmine for reversal of neuromuscular block on the quality of postoperative recovery in elderly adults undergoing video-assisted thoracoscopic lobectomy: a randomised controlled trial. [PDF]

BMC Anesthesiol
Yang Y, Wang Z, He X, Shen X, Jia W, Sheng X, Yao X, Jiao H.   +7 more
europepmc   +1 more source

Presynaptic Congenital Myasthenic Syndromes

Muscle &Nerve, EarlyView.
ABSTRACT Presynaptic congenital myasthenic syndromes (CMS) encompass a large number of rare neurologic disorders caused by impaired release of acetylcholine (ACh) from motor nerve terminals. There are two main groups of presynaptic CMS: one in which the amount of ACh in synaptic vesicles (SV) is diminished and another in which the mechanism of synaptic
Ricardo A. Maselli
wiley   +1 more source

Impact of neuromuscular block monitoring and reversal on postoperative pulmonary complications in thoracic surgery: a Bayesian analysis of the iPROVE-OLV trial. [PDF]

Br J Anaesth
Mazzinari G, Díaz-Cambronero O, Garutti I, Errando CL, Ferrando C, iPROVE-OLV investigators.   +5 more
europepmc   +1 more source

Neuromuscular Block and Blocking Agents in 2018

Turkish Journal of Anesthesia and Reanimation, 2018
openaire   +2 more sources

The Differing Phenotypes of the Three Most Common Postsynaptic Congenital Myasthenic Syndromes Governed by Their Underlying Molecular Pathogenic Mechanisms

Muscle &Nerve, EarlyView.
ABSTRACT The congenital myasthenic syndromes are rare disorders of impaired signal transmission at the neuromuscular junction. Despite next generation sequencing facilitating the identification of variants in myasthenic‐associated genes, these variants are frequently of unknown significance and the clinical diagnosis can be delayed.
David Beeson
wiley   +1 more source

Clinical Characteristics and Treatment Management of Seronegative Myasthenia Gravis: A Systematic Review of the Literature

Muscle &Nerve, EarlyView.
ABSTRACT Seronegative myasthenia gravis (SNMG) is characterized by the absence of detectable autoantibodies against known MG targets, despite clinical and electrophysiological evidence of a postsynaptic neuromuscular junction disorder. The aim of this systematic review was to better define clinical features, diagnostic clues and treatment outcome of ...
Massimiliano Ugo Verza, Mattia Schiavolin, Francesca Beretta, Sara Cornacchini, Antonio Lotti, Gregorio Spagni, Valentina Damato   +6 more
wiley   +1 more source

Deep Neuromuscular Block with Low Pressure Pneumoperitoneum in Laparoscopic Abdominal Surgeries: A Randomized Controlled Trial. [PDF]

Anesth Pain Med
Mohamed Ibrahim A, Said ElSharkawy M, Khalil Abdelrahman R, Elabd Hassan A, Gaber Ibrahim Saad M, Ahmed Elzoughari I, Hussini Ismail Alsayed A, Abdelbadie A, Abd El Fattah Helal R.   +8 more
europepmc   +1 more source

IgG Subclass (IgG1‐4) and IgA Autoantibody Profiles Against Muscle‐Specific Kinase in a Greek Cohort

Muscle &Nerve, EarlyView.
ABSTRACT Introduction/Aims Muscle‐specific kinase myasthenia gravis (MuSK‐MG) is an autoimmune neuromuscular disorder predominantly mediated by IgG4 autoantibodies disrupting MuSK signaling. The contribution of other isotypes remains incompletely defined. We characterized the serological profile of a Greek cohort of MuSK‐MG patients.
Sofia‐Natsοuko Gkotzamani, Maria Pechlivanidou, Francisca Faber, Cansu Elmas, Vasiliki Zouvelou, Elisabeth Chroni, Dimitrios Tzanetakos, Maria Kourouvani, Marlene Wolfsgruber, Ioannis Zaganas, Dimitra Kolovou, Michael Rentzos, Ariadne Daponte, Maria Chondrogiorgi, Spyridon Konitsiotis, Georgios Nicolaou, Stavroula Salakou, Sotirios Giannopoulos, Konstandinos Lazaridis, Georgios Tsivgoulis, Socrates Tzartos, Inga Koneczny, John S. Tzartos   +22 more
wiley   +1 more source